The partnership aims to raise awareness and improve diagnosis of fatty liver disease through blood testing.
Siemens Healthineers and Novo have announced a collaboration to boost awareness and diagnosis of fatty liver disease. The partnership will focus on blood testing as a key diagnostic tool.
The two companies are joining forces to help increase testing and improve detection of the condition. The announcement highlights their shared goal of raising awareness and expanding access to testing.
The Trump administration's preliminary Medicare lab payment cuts could undermine access to critical diagnostic testing, according to the American Clinical Laboratory Association.
A roundup of endocrinology news includes a small trial of stem cells for osteoporosis, new weight-loss data, and a link between bone density and cognition.
A viral sports event controversy reveals how common fecal incontinence is, yet how rarely it is discussed openly.
New FDA rule and $88 million in NIH funding aim to shift drug safety testing toward human-based methods.